Ticker brief
HCM
last close
·
1 day
·
14 days
·
mkt cap
·
signals 14d
5
authors 14d
5
crowd 14d
+0.50
No price history on file for this name (likely non-equity or unlisted) — the “since then” column below stays blank.
Sentiment — last 14 days
daily mean sentiment, 2026-08-17 → 2026-08-28 · now +0.45 (−1 bearish … +1 bullish)
Who spoke5
| author | grade | trader score | signals | mean sent |
|---|---|---|---|---|
| @OpenOutcrier | C | · | 1 | +0.60 |
| @proactive_x | C | +0.24 | 1 | +0.50 |
| @CrweWorld | C | · | 1 | +0.50 |
| @financespotnews | C | -3.33 | 1 | +0.50 |
| @BiopharmIQ | B | · | 1 | +0.40 |
Recent signals5of 5 in 14d — receipts included
| date (PT) | author | sent | what they said | since then | receipt |
|---|---|---|---|---|---|
| 2026-08-28 | @BiopharmIQ | +0.40 | Biotech open summary pairs stock moves with clinical, regulatory and financing events | · | tweet ↗ |
| 2026-08-28 | @financespotnews | +0.50 | HCM won Chinese NMPA approval for ATLED | · | tweet ↗ |
| 2026-08-27 | @CrweWorld | +0.50 | HUTCHMED announces NMPA approval of ATLED for an FGFR2-related cancer indication. | · | tweet ↗ |
| 2026-08-17 | @proactive_x | +0.50 | HUTCHMED's lung-cancer drug trial met key targets, lifting the shares. | · | tweet ↗ |
| 2026-08-17 | @OpenOutcrier | +0.60 | HUTCHMED reported significant survival improvements from ORPATHYS plus TAGRISSO in lung cancer. | · | tweet ↗ |
“Since then” = price move from the close on the signal's date (PT) to the latest close — what happened after they said it, not a backtest. A — means no trading session has closed since the signal yet. Sentiment is our extracted per-tweet score, −1…+1.